S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature

RATIONALE: Apatinib has been proven to significantly prolong the survival of the patients with advanced chemotherapy-refractory gastric cancer. To date, studies on apatinib plus S-1 as first-line palliative therapy for metastatic gastroesophageal junction (GEJ) cancer are rare. PATIENT CONCERNS: A 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chu, Yu, Guang-Mao, Zhang, Miao, Liu, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946331/
https://www.ncbi.nlm.nih.gov/pubmed/31895837
http://dx.doi.org/10.1097/MD.0000000000018691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946331/
https://www.ncbi.nlm.nih.gov/pubmed/31895837
http://dx.doi.org/10.1097/MD.0000000000018691

Ejemplares similares